



Journal Profile



Jurnal Respirasi

eISSN : 26218372 | pISSN :

Universitas Airlangga



S2

Sinta Score

4

H-index

4

H5-Index

61

Citations

61

5 Year Citations

2019


2020

2021



Sinta Accreditations

Citation Statistics



Search...





Page 1 of 8 | Total Records : 72

Publications

Citation

Peran Masker/Respirator dalam Pencegahan Dampak Kesehatan Paru Akibat Polusi Udara  
 HD Faisal, AD Susanto  
 Jurnal Respirasi 3 (1), 18-25

7



## TABLE OF CONTENTS

First-Line Anti-Tuberculosis Drug Resistance Pattern

Chronic Obstructive Pulmonary Disease with Incidence of Heart Failure and Its Influencing Factors

The Effectiveness of Pulmonary Rehabilitation on Pulmonary Function among Adults Patients of COVID-19 Survivors: A Systematic Review

Pin Point Trachea: A Case Report

Bronchial Arteries Embolization in Tuberculosis-Related Recurrent Hemoptysis with Complete Right Lung Atelectasis: A Case Report

Tuberculous Lymphadenitis in Immunocompromised Patients: A Case Report

Kidney-Pulmonary Crosstalk from Pathophysiological Perspective

Chronic Lung and Gastrointestinal Diseases: Take a Broader Perspective


Vitamin D Supplementation and COVID-19

**JURNAL RESPIRASI**

**Vol 8 (1) 2022**

*Jurnal Respirasi now comes in handy:*

[s.id/jurnalrespirasi](https://doi.org/10.24127/jurnalrespirasi)



## INTRODUCTION

**Jurnal Respirasi (JR)** ([p-ISSN: 2407-0831](#), [e-ISSN: 2621-8372](#)) was previously named [Majalah Kedokteran Respirasi \(MKR\)](#) which was established in 2010. The chief editor of MKR was Yusuf Wibisono, dr., Sp.P(K), FCCP. In 2015, MKR changed its name to **JR** with Winariani Koesoemoprodjo, dr., Sp.P(K), MARS, FCCP as its chief editor.

**JR** is a peer-reviewed national journal created by [Department of Pulmonology and Respiratory Medicine](#), Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia. **JR** is published by Universitas Airlangga, Surabaya, Indonesia. **JR** is published three times a year, every January, May, & September, and contains 9 (nine) complete texts in English. **JR** provides a forum for original articles, case reports, and literature reviews.

## ACCREDITATION

**Jurnal Respirasi** has been accredited as a **SINTA 2** journal based on the [Decree of the Director General of Research and Development Strengthening RISTEK-BRIN No.B/1796/E5.2/KI.02.00/2020](#) on December 30<sup>th</sup>, 2020.

## INDEXATION

**Jurnal Respirasi** has also been accepted for indexation in [DOAJ](#) on January 3<sup>rd</sup>, 2022.

## INDEXED BY:



JR ([p-ISSN: 2407-0831](#), [e-ISSN: 2621-8372](#)) is licensed under [Creative Commons Attribution-ShareAlike 4.0 International License](#).

## EDITOR IN CHIEF

[Winariani Koesoemoprodjo, dr., Sp.P\(K\), MARS, FCCP](#), Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

## DEPUTY EDITOR

[Dr. Isnin Anang Marhana, dr., Sp.P\(K\), FCCP, FISR, FAPSR](#), Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

## HONORARY EDITOR

1. [Prof. Dr. Budi Santoso, dr., Sp.OG\(K\)](#), Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
2. [Dr. Achmad Chusnu Romdhoni, dr., Sp.T.H.T.K.L\(K\), FICS](#), Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
3. [Dr. Hanik Badriyah Hidayati, dr., Sp.S\(K\)](#), Department of Neurology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
4. [Dr. Sulistiawati, dr., M.Kes.](#), Department of Public Health and Preventive Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

## EDITORIAL BOARD MEMBERS

1. [Prof. Jae Gook Shin, MD., Ph.D.](#), Department of Pharmacology and Clinical Pharmacology, Inje University College of Medicine, Korea, Republic of
2. [Chung-yu Chen, MD., M.Sc., Ph.D.](#), Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, College of Medicine, National Taiwan University, China
3. [Dr. Laksmi Wulandari, dr., Sp.P\(K\), FCCP](#), Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
4. [Dr. dr. Irawaty Djaharuddin Muzakkir, Sp.P\(K\)](#), Department of Internal Medicine, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia
5. [Prof. Dr. Muhammad Amin, dr., Sp.P\(K\)](#), Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
6. [Haryati, dr., Sp.P\(K\), FIPSR, FAPSR](#), Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Lambung Mangkurat, Banjarmasin, Indonesia, Indonesia
7. [Marwan, dr., M.Kes., Sp.P](#), Faculty of Medicine, Mulawarman University, Samarinda, Indonesia, Indonesia

## MANAGING EDITOR

[Alfian Nur Rosyid, dr., Sp.P\(k\), FAPSR., FCCP](#), Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia

## ASSISTANT EDITOR

1. [Laila Maulida Hidayah, S.KM.](#), Universitas Airlangga, Indonesia
2. [Cindy Belinda Ramadhanty, S.Hum., M.Hum.](#), Universitas Airlangga, Indonesia

## FOCUS AND SCOPE

This journal publishes various scientific works on the medical world, especially in the field of Pulmonology and Respiratory Medicine, such as:

- Acute and Chronic Obstructive Pulmonary Disease
- Airway Inflammation
- Allergy and Immunology
- Critical Care Respiratory
- Epidemiology of Lung Disease
- Lung Disease
- Occupational Respiratory Disease
- Pulmonary Infection
- Pulmonary Intervention
- Pulmonary Oncology
- Smoking-Related Lung Disease

## METADATA

Metadata associated with this Archival Unit includes:

Journal URL	<a href="https://e-journal.unair.ac.id/JR">https://e-journal.unair.ac.id/JR</a>
Title	Jurnal Respirasi
Publisher	<a href="#">Faculty of Medicine Universitas Airlangga</a>
Description	Jurnal Respirasi (JR)
Keywords	Tuberculosis; Pneumonia; Lung Cancer; Asthma; Chronic Obstructive Pulmonary Disease (COPD); Asthma-COPD Overlap Syndrome (ACOS); Mediastinal Tumor; Pleural Effusion; Pneumothorax; Fluidopneumothorax; Chemotherapy; Radiotherapy; Superior Vena Cava Syndrome (SVCS); Cor Pulmonale; Atelectasis; Hemoptysis; Respiratory Distress; Lung Work; Pneumoconiosis; Obstructive Sleep Apnea (OSA); Lung Mycosis; Pneumocystis carinii; Middle East Respiratory Syndrome Coronavirus (MERS CoV); Severe Acute Respiratory Syndrome (SARS); Endobronchial Ultrasound Bronchoscopy Procedure (EBUS); Pleurodesis; Thoracoscopy; Thoracocentesis; Ventilator; Non-Invasive Ventilation (NIV); Public Health; Respiratory Medicine
Language(s)	English (en_US)
Publisher Email	<a href="mailto:respirasi@journal.unair.ac.id">respirasi@journal.unair.ac.id</a>
Copyright	<ol style="list-style-type: none"><li>1. The journal allows the author to hold the copyright of the article without restrictions.</li><li>2. The journal allows the author(s) to retain publishing rights without restrictions</li><li>3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).</li><li>4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under “the same, similar or a</li></ol>

compatible license". Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.



LOCKSS system has permission to collect, preserve, and serve this Archival Unit.



Open Journal Systems was developed by the Public Knowledge Project.






## TABLE OF CONTENTS

<b>ORIGINAL ARTICLE</b>	<b>Pages</b>
<b>First-Line Anti-Tuberculosis Drug Resistance Pattern</b> <i>Ayurveda Zaynabila Heriqbaldi, Rebekah Juniati Setiabudi, Resti Yudhawati Meliana</i>	1-6
<b>Chronic Obstructive Pulmonary Disease with Incidence of Heart Failure and Its Influencing Factors</b> <i>Andry Wahyudi Agus, Adrianison Adrianison, Dyah Siswanty, Faisal Yunus, Zahtamal Zahtamal</i>	7-14
<b>The Effectiveness of Pulmonary Rehabilitation on Pulmonary Function among Adults Patients of COVID-19 Survivors: A Systematic Review</b> <i>Hasanudin Hasanudin, Tintin Sukartini, Makhfudli Makhfudli, Alfian Nur Rosyid, Natalia Christin Tiara Revita, Handira Nadhifatul Aini</i>	15-25
<b>CASE REPORT</b>	26-32
<b>Pin Point Trachea: A Case Report</b> <i>Ni Wayan Candrawati, Venny Singgih, Ketut Putu Yasa, Ida Bagus Ngurah Rai</i>	
<b>Bronchial Arteries Embolization in Tuberculosis-Related Recurrent Hemoptysis with Complete Right Lung Atelectasis: A Case Report</b> <i>Yulia Devina Suci Kusumastrini, Ariani Permatasari</i>	33-38
<b>Tuberculous Lymphadenitis in Immunocompromised Patients: A Case Report</b> <i>Edward Pandu Wiriansya, Irawaty Djaharuddin, Andi Tiara Salengke Adam</i>	39-43
<b>REVIEW ARTICLE</b>	
<b>Kidney-Pulmonary Crosstalk from Pathophysiological Perspective</b> <i>Sharifa Audi Salsabila, Alfian Nur Rosyid, Maulana Antiyan Empitu, Ika Nindya Kadariswantiningsih, Satriyo Dwi Suryantoro, Mutiara Rizki Haryati, Mochammad Thaha, Yusuke Suzuki</i>	44-51
<b>Chronic Lung and Gastrointestinal Diseases: Take a Broader Perspective</b> <i>Syifa Mustika, Tiar Oktavian Effendi</i>	52-59
<b>Vitamin D Supplementation and COVID-19</b> <i>Gracia Dewitacita Tanaya, Ayu Hutami Syarif</i>	60-68

## ORIGINAL ARTICLE

# First-Line Anti-Tuberculosis Drug Resistance Pattern

Ayurveda Zaynabila Heriqbaldi<sup>1</sup> , Rebekah Juniati Setiabudi<sup>2,4\*</sup> , Resti Yudhawati Meliana<sup>3,4</sup> 

<sup>1</sup>Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

<sup>2</sup>Department of Microbiology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

<sup>3</sup>Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.

<sup>4</sup>Dr. Soetomo General Hospital, Surabaya, Indonesia.

## ARTICLE INFO

### Article history:

Received 26 July 2021

Received in revised form 10 January 2022

Accepted 13 January 2022

Available online 30 January 2022

### Keywords:

Drug resistance patterns,  
First-line anti-tuberculosis drugs,  
Tuberculosis.

## ABSTRACT

**Introduction:** Tuberculosis (TB) is a disease caused by *Mycobacterium tuberculosis* and usually attacks the lungs. Indonesia is in the third rank of TB cases in the world. An important concern regarding TB currently is the case of anti-TB drug resistance, hence research on resistance patterns and risk factors is essential. This study aimed to identify the pattern of first-line anti-TB drug resistance at Dr. Soetomo General Hospital, Surabaya.

**Methods:** A descriptive retrospective study was conducted at Dr. Soetomo General Hospital, Surabaya for the period of 2017-2019. The samples were obtained through total population sampling of 239 pulmonary TB patients with first-line anti-TB drug resistance which were registered at MDR-TB Polyclinic Dr. Soetomo General Hospital, Surabaya. Only complete medical records were included. The variables were first-line anti-TB drug resistance (isoniazid, rifampicin, ethambutol, streptomycin) and patients' characteristics (age, gender, treatment history, and comorbidities). The drug resistance test was performed using certified culture methods.

**Results:** Among 239 patients, the incidences of resistance to H, R, E, and S were 79.08%, 94.14%, 25.94%, and 20.08%, respectively. The most common patterns were HR (42.26%), R (18.83%), and HRE (12.55%). The largest age group was 45-54 years old (38%). The dominant gender was male (56.49%). The most treatment history category was relapsed patients (48%) and there were more patients with comorbidity (57%).

**Conclusion:** The highest incidence rate of resistance was rifampicin and the most common resistance pattern was HR. Most of the patients were of working age, male, relapse patients, and had comorbidities. An appropriate TB therapy treatment plays an important role in preventing resistance.

## INTRODUCTION

Tuberculosis (TB) is a disease caused by *Mycobacterium tuberculosis* (MTB) which usually attacks the lungs.<sup>1</sup> Indonesia is in the third place with the most TB cases in the world. In 2017, it was estimated that the total TB cases in Indonesia reached 842,000, then increased in 2018 to 845,000.<sup>2,3</sup> An important concern regarding TB disease today is the case of multi drug resistance TB (MDR-TB). In 2017, MDR/RR-TB cases in Indonesia reached 23,000 cases.<sup>2</sup> Meanwhile, in 2018, multi-drug resistance (MDR) or rifampicin resistance TB (RR-TB) cases in Indonesia reached 24,000 cases.<sup>3</sup>

MDR-TB is one of the main challenges in global TB control. Treatment of MDR-TB takes longer time and is more complex, such as requiring many drugs including second-line injectable drugs. Second-line drugs have more significant side effects, thus making medication adherence more difficult to achieve.<sup>4</sup> MDR-TB can be caused by two main reasons, inappropriate TB treatment and person-to-person transmission. Inappropriate use of antimicrobials such as single drug consumption, poor quality drugs, and early discontinuation of treatment can lead to drug resistance which then can be transmitted.<sup>5,6</sup>

\*Corresponding author: [rebekahsetiabudi@gmail.com](mailto:rebekahsetiabudi@gmail.com)



Several studies have been performed in various countries. One of which is an observational study in India which found that 71.1% patients experienced resistance to at least one type of anti-TB drug. The highest prevalence of resistance pattern was isoniazid as much as 61.7%, followed by rifampicin (57.0%), streptomycin (50.6%), ethambutol (40.8%), and 52.8% of them were MDR-TB.<sup>7</sup> Study on the pattern of first-line anti-TB drug resistance was also performed in Germany by in the period of 2008-2017. From this study, there were four dominant patterns, namely streptomycin (3.1%), isoniazid (2.9%), isoniazid and streptomycin (2.1%), and pyrazinamide (1.6%).<sup>8</sup>

In addition, study on risk factors is important to look at the populations which have the risk of developing anti-TB drug resistance. Age is an important factor. People aged 10-25 years old can be at risk related to medication adherence.<sup>9</sup> History of previous TB treatment such as failed category 1 TB cases, relapsed TB cases, and dropped out of treatment are groups at high risk of developing resistance.<sup>10</sup> Comorbidity can also be a risk factor for anti-TB drug resistance associated with decreased immunity.<sup>11</sup>

Based on the differences in first-line anti-TB drug resistance patterns in various places and the previously mentioned facts, there are several opportunities in the development of studies on first-line anti-TB drug resistance patterns in Indonesia. In addition, this study is important because the incidence of MDR-TB is still high due to various factors as previously described. Therefore, this study discussed the pattern of first-line anti-TB drug resistance at Dr. Soetomo General Hospital, Surabaya. This study also considered risk factors by identifying the patients' age, gender, treatment history, and comorbidities.

## METHODS

This was a retrospective descriptive study of first-line anti-TB drug resistance pattern at Dr. Soetomo General Hospital, Surabaya in the period of 2017-2019. The data were obtained from the patients' medical record. Ethical licensing was submitted to and approved by the Research Ethics Commission of Dr. Soetomo General Hospital (No.0189/LOE/301.4.2/XI/2020).

The sample of this study was taken by total sampling technique and were all TB patients with first-line anti-TB drug resistance which were registered at MDR-TB Polyclinic based on inclusion and exclusion criteria. The inclusion criteria were pulmonary TB patients with first-line drug resistance based on the antibiotic sensitivity tests in medical records and were registered in the period of 2017-2019. The exclusion criteria were patients with incomplete medical record data.

The variables used in this study were first-line anti-TB drug resistance (isoniazid, rifampicin, ethambutol, streptomycin) and patients' characteristics (age, gender, treatment history, and comorbidity). The resistance test was performed using certified culture methods with Lowenstein Jensen and BACTEC MGIT. Category of treatment history was based on the guidelines of the Ministry of Health.<sup>12</sup> Comorbidities were other diseases suffered by patients, namely diabetes mellitus, hypertension, and human immunodeficiency virus (HIV). Data analysis was performed descriptively.

## RESULTS

### The Incidence of First-Line Anti-Tuberculosis Drug Resistance

Total patients with first-line anti-TB drug resistance were 346 patients. However, the samples that met the inclusion criteria were 239 patients. The following is the incidence of resistance to first-line anti-TB drugs (Table 1).

Of the four first-line anti-TB drugs, the highest incidence of resistance was rifampicin. Based on the trend, the drug which experienced an increase from 2017 to 2019 was isoniazid and the other three drugs had fluctuating trends.

### First-Line Anti-Tuberculosis Drug Resistance Pattern

The following table shows the drug resistance pattern consisting of monoresistance, a combination of two drugs, three drugs, and four drugs (Table 2).

**Table 1.** Incidence of first-line anti-tuberculosis drug resistance

Drug	2017 (n = 79)	2018 (n = 63)	2019 (n = 97)	Total (n = 239)
Isoniazid				
n	60	49	80	189
%	75.95%	77.78%	82.47%	79.08%
Rifampicin				
n	74	60	91	225
%	93.67%	95.24%	93.81%	94.14%
Ethambutol				
n	20	17	25	62
%	25.32%	26.98%	25.77%	25.94%
Streptomycin				
n	17	14	17	48
%	21.52%	22.22%	17.52%	20.08%

**Table 2.** First-line anti-tuberculosis drug resistance pattern

Number of Drug	Drug				Total patients (n = 239)	%
	H	R	E	S		
1	+				9	3.77%
		+			45	18.83%
			+		1	0.42%
				+	0	0.00%
2	+	+			101	42.26%
	+		+		2	0.84%
	+			+	1	0.42%
		+	+		3	1.26%
		+		+	1	0.42%
			+	+	0	0.00%
3	+	+	+		30	12.55%
	+	+		+	20	8.37%
	+		+	+	1	0.42%
		+	+	+	0	0.00%
4	+	+	+	+	25	10.46%

H: isoniazid, R: rifampicin, E: ethambutol, S: streptomycin

**Table 3.** Patients' characteristics

Variable	N (n = 239)	%
<b>Age</b>		
<15 years old	2	1%
15-24 years old	11	5%
25-44 years old	70	29%
45-54 years old	92	38%
55-64 years old	52	22%
>64 years old	12	5%
<b>Gender</b>		
Male	135	56.49%
Female	104	43.51%
<b>Treatment History</b>		
New case	48	20%
Relapse	115	48%
Failed treatment	4	2%
Loss to follow up	37	15%
Others	10	4%
Unknown	3	1%
<b>Comorbidities</b>		
Yes	137	57%
No	102	43%

The most common pattern in the period of 2017 to 2019 was isoniazid, rifampicin (HR), which was 101 patients (42.26%), followed by R monoresistance (18.83%), and isoniazid, rifampicin, ethambutol (HRE) (12.55%). Meanwhile, based on the number of drugs, the highest incidence was resistance to two types of drugs.

### Patients' Characteristics

Patients' characteristics consisting of age, gender, treatment history, and comorbidities can be seen in [Table 3](#). Among 239 patients, it was found that the most age group was 45-54 years old (38%), most dominant gender were male (56.49%), dominated by relapse cases (48%), and more patients had comorbidity (57%).

## DISCUSSION

### The Incidence of First-Line Anti-Tuberculosis Drug Resistance

The highest incidence of resistance among the first-line anti-TB drug was rifampicin. Meanwhile, based on the trend, the drug which experienced an increase from 2017 to 2019 was isoniazid. Another study conducted in Ethiopia in 2015-2016 found the incidence of rifampicin resistance was 89 out of 226 patients (39.4%) which still had lower prevalence than isoniazid.<sup>13</sup>

In this study, rifampicin resistance was found to have the highest incidence when compared to the other drugs. History of previous TB treatment is a strong risk factor for MDR-TB. This can be caused by poor drug quality, repetition, or even taking the wrong medication. The likelihood of developing RR-TB was three times higher in previously treated patients than in new patients. In addition, the development of better diagnostic tools, especially the use of GeneXpert, can also increase the discovery of rifampicin resistance.<sup>14</sup>

This study shows the incidence of isoniazid resistance experienced an increase from 2017 to 2019. This is slightly different from a study in China, which showed a significant decrease in isoniazid resistance from 128 patients (45.6%) to 89 patients (29.1%). This decrease may be due to improvements in TB treatment in Hangzhou through the directly observed therapy short course (DOTS) Plus.<sup>15</sup> Meanwhile, the increase of cases in Indonesia can be influenced by many factors, ranging from patient factors, environment, and diseases.<sup>16</sup>

The numbers of ethambutol resistance in 2017-2019 were 62 patients (25.94%). Compared to other drugs, the incidence of ethambutol resistance was not too high. This is also supported by a study in Germany which obtained results from 3,324 patients with anti-TB drug resistance, only 13 patients (0.4%) of whom experienced ethambutol resistance.<sup>8</sup>

Meanwhile, the total numbers of streptomycin resistance in 2017-2019 were 48 patients (20.08%). In previous studies, streptomycin resistance is the second highest incidence after isoniazid.<sup>13,17</sup> A study in Ethiopia found the incidence of streptomycin resistance was 94 out of 226 patients (41.6%).<sup>13</sup> A study in China obtained results from 2,678 resistant cases, in which 1,811 patients experienced streptomycin resistance (67.6%).<sup>17</sup> This can be caused by prolonged and frequent use of streptomycin.<sup>8</sup>

### First-Line Anti-Tuberculosis Drug Resistance Pattern

In this study, the most common pattern in the period of 2017 to 2019 was HR with 101 patients (42.26%), followed by R and HRE. Based on the number of drugs, the highest incidence was resistances to two types of drugs. The results of this study are supported by previous study conducted at Dr. Soetomo General Hospital, Surabaya for the period of August 2009-April 2018. The study was conducted on a population of MDR-TB patients and showed that the highest first-line drug resistance pattern was HR as many as 204 of 433 patients (47%), followed by HRE (26%), and HRES (16%).<sup>18</sup>

In addition, another study in Riau, Indonesia showed the same results, in which the most common pattern was HR with as many as 9 out of 18 patients (50%), followed by HRE and isoniazid, rifampicin, ethambutol, streptomycin (HRES).<sup>19</sup> Another study in Balikpapan, Indonesia also showed that the dominant pattern was HR in 5 of 15 patients (33.3%) and followed by isoniazid, rifampicin, pyrazinamide, ethambutol (HRZE) in 2 patients (13.3%).<sup>10</sup>

Based on several studies in Indonesia, the dominant pattern of first-line anti-TB drug resistance in Indonesia is HR.<sup>10,18,19</sup> This may be due to the fact that isoniazid and rifampicin are the first-line active drugs in TB therapy. Therefore, the possibility of isoniazid and rifampicin used as monotherapy or in combination with other antibiotics is higher.<sup>19</sup> Isoniazid resistance is often related to its use as an essential drug in TB therapy and TB prophylaxis in certain populations.<sup>13</sup>

Another study in Germany showed that from 3,324 patients, there were four dominant patterns, S (24.5%), H (23.1%), HS (16.6%), and Z (12.4%). High proportions of streptomycin and isoniazid resistance

have been found in the German population and some other populations, especially those born in Eastern Europe. Monoresistance to streptomycin was the most common pattern of drug resistance in cases born in Germany and outside Germany. This is most likely due to a long history of streptomycin use.<sup>8</sup>

In this study, the highest incidence of resistance was found to be the resistance to two types of first-line anti-TB drugs, which was 45.2% and dominated by the HR pattern. The high incidence of isoniazid resistance may be due to the widespread use of the drug in the first-line treatment of TB patients.<sup>13</sup> This result is slightly different from the previous study which showed the highest incidence of resistance was four types of first-line anti-TB drugs, HRES, with the prevalence of 66%. Poly-resistance to anti-TB drugs may be associated with the history of previous treatment.<sup>20</sup>

### Patients' Characteristics

The most dominant age group in patients with first-line anti-TB drug resistance was 45-54 years old consisting 92 patients (38%). This was supported by a study in China which showed the most dominant age group was 35-55 years old (39%).<sup>21</sup> Based on the study, it can be seen that the most common age group was the working age group, which is a population aged 15 to 64 years old.<sup>22</sup> This age group is mostly exposed to TB cases. It may be the reason this age group is more vulnerable.<sup>7</sup> In addition, high-risk behavior and the tendency to stop TB treatment can also affect the occurrence of resistance.<sup>9</sup>

This study found the number of male patients was 135 patients (56.49%). This is supported by previous study which found that there were more male patients as many as 56 patients (59%).<sup>7</sup> Another study in Germany also found more male patients as many as 1,617 patients (61%).<sup>8</sup> This can be influenced by several factors such as difficulty in accessing and utilizing health facilities in the study area, social contact, exposure to dust, smoking habits, and alcohol consumption.<sup>23</sup>

Based on the history of treatment, most patients were relapse patients as many as 115 patients (48%). Another study on MDR-TB patient in Riau also showed that the most common treatment history was relapse cases with 15 patients (83.3%).<sup>19</sup> Previous study conducted at Dr. Soetomo General Hospital, Surabaya in the period of August 2009 to April 2018 showed the same results in MDR-TB patients which found the most common treatment history was relapse patients as many as 160 patients (37%).<sup>18</sup> Relapse patient means a patient who had previously been treated and declared cured, fell ill again either due to relapse or reinfection. Relapse is often associated with poor treatment outcomes and a higher mortality rate compared to primary TB infection.<sup>24</sup>

In this study, it was found that among 239 patients, 137 patients (37%) had comorbidity. The comorbidities referred to in this study include diabetes mellitus, hypertension, and HIV. This study is supported by previous study conducted in Nigeria in the period of 1 August 2014 to 31 March 2017. The results showed that from 565 patients with drug resistance, more patients had comorbidities as many as 397 patients (70.3%). Comorbidities in this study include anemia, hypokalemia, hypothyroidism, and HIV.<sup>14</sup> In pulmonary TB patients with diabetes mellitus, higher numbers of bacteria were found at the start of therapy, thus there was a higher possibility of mutations and the occurrence of MDR-TB with large numbers of bacteria. Therefore, in these patients, longer therapy is needed.<sup>25</sup> HIV is one of the risk factors for TB associated with dysregulation of the immune system. It has been said that HIV infection may lead to malabsorption of anti-TB drugs and is associated with acquired rifampicin resistance.<sup>20</sup>

## CONCLUSION

The highest incidence rate of resistance was rifampicin and the most common resistance pattern was HR. Most of the patients were of working age, male, relapse patients, and had comorbidity. An appropriate TB therapy treatment plays an important role in preventing resistance. Furthermore, it is necessary to improve education and support efforts for TB and drug resistance TB patients to improve patient compliance and achieve treatment success. Further research using analytical methods to identify and analyze risk factors which influence drug resistance TB cases may be needed.

## Acknowledgments

The authors would like to thank Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Airlangga/Dr. Soetomo General Hospital, Surabaya, Indonesia for facilitating and supporting this study.

## Conflict of Interest

The author stated there is no conflict of interest in this study.

## Funding

This study does not receive any funding.

## Authors' Contributions

Designing the study, estimating & analyzing the issues: AZH. Reshaping the discussion: RJS. Reshaping the methods: RYM. All the authors accept the final version.

## REFERENCES

1. WHO. *Tuberculosis*. Geneva, 2021. [cited December 23, 2021]. Available from [[WebPage](#)]
2. WHO. Global Tuberculosis Report 2018. *Geneva*, [cited December 23, 2021]. Available from [[WebPage](#)]
3. WHO. *WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment*. Geneva, 2019[cited December 23, 2021]. Available from [[WebPage](#)]
4. Paul R. The Threat of Multidrug-Resistant Tuberculosis. *J Glob Infect Dis* 2018; 10: 119–120. [[CrossRef](#)]
5. WHO. *Tuberculosis: Multidrug-Resistant Tuberculosis (MDR-TB)*. Geneva, 2018. [cited December 23, 2021]. Available from [[WebPage](#)]
6. Soedarsono. Tuberculosis: Development of New Drugs and Treatment Regimens. *Jurnal Respirasi*. 2021; 7(1): 36-45.
7. Sinha P, Srivastava GN, Gupta A, *et al*. Association of Risk Factors and Drug Resistance Pattern in Tuberculosis Patients in North India. *J Glob Infect Dis* 2017; 9: 139–145. [[CrossRef](#)]
8. Glasauer S, Altmann D, Hauer B, *et al*. First-Line Tuberculosis Drug Resistance Patterns and Associated Risk Factors in Germany, 2008-2017. *PLoS One* 2019; 14: e0217597. [[CrossRef](#)]
9. Workicho A, Kassahun W, Alemseged F. Risk Factors for Multidrug-Resistant Tuberculosis among Tuberculosis Patients: A Case-Control Study. *Infect Drug Resist* 2017; 10: 91–96. [[CrossRef](#)]
10. Adiwinata R, Rasidi J, Marpaung M. Clinical Profile and Treatment Evaluation of Rifampicin-Resistant and Multidrug-Resistant Tuberculosis Patients at Dr. Kanujoso Djatiwibowo Public Hospital, Balikpapan. *J Respirologi Indones* 2018; 38: 135–142. [[CrossRef](#)]
11. Wijayanto M, Arnanda R, Thamrin Edo. Risk Factors for Development of Multidrug-Resistant Tuberculosis among Relapsed Patients in West Papua, Indonesia: A Descriptive and Analytical Study. *Int J Appl Pharm* 2019; 11: 50–55. [[CrossRef](#)]
12. Kementerian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/755/2019 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Tuberculosis. HK.01.07/MENKES/755/2019, Indonesia, 2019. [cited December 24, 2021]. Available from [[WebPage](#)]
13. Mesfin EA, Beyene D, Tesfaye A, *et al*. Drug-Resistance Patterns of Mycobacterium tuberculosis Strains and Associated Risk Factors among Multi Drug-Resistant Tuberculosis Suspected Patients from Ethiopia. *PLoS One* 2018; 13: e0197737. [[CrossRef](#)] [[PubMed](#)]

14. Adejumo OA, Olusola-Faleye B, Adepoju V, *et al.* Prevalence of Rifampicin Resistant Tuberculosis and Associated Factors among Presumptive Tuberculosis Patients in a Secondary /Referral Hospital in Lagos Nigeria. *Afr Health Sci* 2018; 18: 472–478. [[CrossRef](#)]
15. Li Q, Zhao G, Wu L, *et al.* Prevalence and Patterns of Drug Resistance among Pulmonary Tuberculosis Patients in Hangzhou, China. *Antimicrob Resist Infect Control* 2018; 7: 61. [[CrossRef](#)]
16. Allué-Guardia A, García JI, Torrelles JB. Evolution of Drug-Resistant Mycobacterium tuberculosis Strains and Their Adaptation to the Human Lung Environment. *Front Microbiol* 2021; 12: 612675. [[CrossRef](#)]
17. Song W, Li Y, Ma X, *et al.* Primary Drug Resistance of Mycobacterium tuberculosis in Shandong, China, 2004–2018. *Respir Res* 2019; 20: 223. [[CrossRef](#)]
18. Soedarsono S, Mertaniasih NM, Sulistyowati T. First Line Anti-Tuberculosis Drug Resistance Pattern In Multidrug-Resistant Pulmonary Tuberculosis Patients Correlate with Acid Fast Bacilli Microscopy Grading. *Indones J Trop Infect Dis* 2020; 8: 1–8. [[CrossRef](#)]
19. Putri VA, Yovi IY, Fauzia D. Profil Pasien Tuberculosis Multidrug Resistance (TB-MDR) di Poliklinik TB-MDR RSUD Arifin Achmad Provinsi Riau Periode April 2013-Juni 2014. *J Online Mhs Fak Kedokt Univ Riau* 2015; 2: 1–17. [[CrossRef](#)]
20. Ibrahim E, Baess AI, Al Messery MA. Pattern of Prevalence, Risk Factors and Treatment Outcomes among Egyptian Patients with Multidrug Resistant Tuberculosis. *Egypt J Chest Dis Tuberc* 2017; 66: 405–411. [[CrossRef](#)]
21. Cao Z, Lan Y, Chen L, *et al.* Resistance to First-Line Antituberculosis Drugs and Prevalence of pncA Mutations in Clinical Isolates of Mycobacterium tuberculosis from Zunyi, Guizhou Province of China. *Infect Drug Resist* 2019; 12: 3093–3102. [[PubMed](#)]
22. Development O for EC and. *OECD Data: Working Age Population*. Paris, 2021. [[GoogleScholar](#)]
23. More SW, Parande MA, Kamble SW, *et al.* Profile of Drug-Resistant Tuberculosis in Western Maharashtra. *J Fam Med Prim Care* 2017; 6: 29–33. [[CrossRef](#)] [[PubMed](#)]
24. Naidoo K, Dookie N. Insights into Recurrent Tuberculosis: Relapse Versus Reinfection and Related Risk Factors. In: *Tuberculosis*. 2018. Epub ahead of print 26 September 2018. DOI: 10.5772/intechopen.73601. [[GoogleScholar](#)]
25. Rumende CM. Risk Factors for Multidrug-resistant Tuberculosis. *Acta Medica Indonesiana* 2018; 50: 1–2. [[PubMed](#)]